What Are the Challenges in Targeting EGFR Amplification?
Despite the availability of EGFR-targeted therapies, challenges remain in effectively treating cancers with EGFR amplification. One major issue is the development of resistance to EGFR TKIs. Tumors can acquire secondary mutations, activate alternative signaling pathways, or undergo phenotypic transformations to evade treatment. Combination therapies and the development of next-generation inhibitors are ongoing areas of research to overcome these challenges.
